HDAC inhibitors promote pancreatic stellate cell apoptosis and relieve pancreatic fibrosis by upregulating miR-15/16 in chronic pancreatitis

Ting Ji1 · Weiguang Feng2 · Xiangcheng Zhang1 · Kui Zang1 · Xingxing Zhu1 · Futai Shang1

Received: 1 March 2020 / Accepted: 4 June 2020 / Published online: 11 June 2020
© The Author(s) 2020

Abstract
In chronic pancreatitis, PSCs are activated by proinflammatory cytokines to induce pancreatic fibrogenesis. HDAC inhibition protected against the pancreatic fibrosis and the apoptosis of PSCs through induced apoptosis and depressed inflammation. In our study, we found that miR-15 and miR-16 decreased significantly in chronic pancreatitis and HDAC inhibition could recover the levels of these two miRNAs. HDAC regulated the transcription of miR-15 and miR-16, which then modulate the apoptosis and fibrosis of PSCs. And we proved that Bcl-2 and Smad5 were the target genes of miR-15 and miR-16, which illustrated how HDAC inhibition alleviated the apoptosis and fibrogenesis of PSCs in chronic pancreatitis. These results suggested that HDAC inhibition protects against CP by promoting apoptosis and TGF-β/Smads signaling pathways, and indicated that HDAC inhibition is a potential therapy to alleviate CP patients in clinic, and these need to be explored further.

Keywords Chronic pancreatitis · HDAC inhibition · Apoptosis · miR-15/miR-16

Introduction
Chronic pancreatitis (CP) usually came from long-term damage to the pancreas, eventually caused endocrine and exocrine deficiency characterized by malnutrition and diabetes [1, 2]. The histologic features of CP include chronic inflammatory, fibrosis, acinar cell atrophy or distorted or blocked ducts [2–4]. Once damaged, pancreatic stellate cells (PSCs) are activated by proinflammatory cytokines to induce pancreatic fibrogenesis [5]. They can secrete excessive amounts of extracellular matrix (ECM) proteins which comprise fibrous tissue [6, 7]. Many researchers have attempted to identify how inflammation and apoptosis of the PSCs caused chronic pancreatitis eventually, but the details of the mechanism were still unknown.

HDAC enzymes involve removing the acetyl group from the histones comprising the nucleosome, and decreased levels of acetylation are usually associated with repression of gene expression [8, 9]. In recent years, HDAC inhibitors have emerged as a novel class of agents that regulate chromatin structure and gene expression, inducing growth inhibition, apoptosis, and differentiation, such as Vorinostat (SAHA) and Trichostatin A (TAS) [10–12].

TGF-β is a special growth factor and at the same time is chemotactic for fibroblasts, stimulates fibroblast proliferation, and increases the synthesis of a number of extracellular matrix proteins [13, 14]. It promotes the initiation and progression of pancreatic fibrosis through matrix production and growth control of the pancreatic stellate cells in vitro [15–17]. The Smads are a family of intracellular regulatory proteins that act downstream of the TGF-β Type I receptor. Once activated, Smad complex could translocate to the nucleus where it is recruited to DNA to regulate the transcription of specific genes [18, 19]. Smad7, as one of the inhibitory Smads, which antagonize the activity of the receptor-regulated Smads [20, 21]. Abnormal Smad signaling is likely to be related to the onset and progression of fibrosis [22–24].
It is well known that miRNAs are involved in a variety of biological processes, including cell proliferation, differentiation, apoptosis, and inflammation [25–27]. Abnormal expression of miRNAs is often associated with pathological disorders [28, 29]. Therefore, the identification of abnormally expressed miRNAs will be helpful in further understanding of CP [30, 31]. Some study has reported that miR-15 and miR-16 may regulate the expression of Bcl-2, an important apoptosis-related protein [32]. Moreover, It has been learned that miR-15a/miR-16 cluster suppressed TGF-β signaling pathway through Smads expression in tumor invasion [33]. Therefore, we focused our further study on miR-15 and miR-16, explored the relationship between them and the apoptosis and fibrosis of activated PSCs in vitro.

In this study, we found that HDAC inhibition could rescue the pancreatic fibrosis in chronic pancreatitis through increased expression of miR-15 and miR-16. The abnormal surplus miR-15 and miR-16 in pancreatic tissues from chronic pancreatitis restored after HDAC inhibition. And related pathological damage such as fibrosis and inflammation were alleviated as well. The apoptosis of PSCs was promoted after either overexpression of miR-15 or miR-16 or HDAC inhibition, but TGF-β/Smads signaling pathway were repressed at the same time. According to our research, HDAC inhibition could induce the transcription of miR-15 and miR-16, additionally both Bcl-2 and Smad5 were the target genes of miR-15 and miR-16. These results suggested that HDAC inhibition protected against the pancreatic fibrosis and the apoptosis of PSCs through induced apoptosis and depressed inflammation by increased miR-15 and miR-16. So HDAC inhibitors are potential therapies to treat CP patients in the future.

Materials and methods

Animals and induction of CP

Male Sprague–Dawley rats used in this study were purchased from Slac Laboratory Animal Company (Shanghai, China). Animals were maintained on a 12 h light/12 h dark cycle at 22 °C, given ad libitum access to food and water. All experiments were conducted with the approval of the Animal Research Committee at Changzhou City No. 1 People’s Hospital. Chronic pancreatitis model was induced as previously described [34]. Briefly, food was withdrawn 12 h prior to induction, the common bile duct was closed temporarily near the liver with a small vascular clamp. A blunt 24-gauge needle was inserted into the duodenum and guided through the papilla into the duct and was secured with suture. 0.5 ml TNBS (trinitrobenzene sulfonic acid) solution (2%) in 10% ethanol in PBS was infused into the pancreatic duct. After 30 min, needle and suture line were removed, the hole in the duodenum was sutured, whereas, in the control group, saline was infused instead of TNBS.

Reagents and drugs

Vorinostat (SAHA) and Trichostatin A (TSA) were purchased from MedChem Express (Shanghai, China). Anti-GFAP (sc-33673) was purchased from Santa Cruz (Dallas, TX, USA). Anti-α-SMA (A5228), Anti-Desmin (D1033), Anti-acetyl-Histone H3 (H9286), Anti-acetyl-Histone H4 (SABS600021) and Anti-actin (A5060) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Anti-Cleaved Caspase-9 (9507), Anti-Cleaved Caspase-3 (5A1E), Anti-Smad5 (12534) were purchased from Cell Signaling (Beverly, MA, USA). Anti-Smad7 (42-0400) and Bcl-2 (13-8800) were purchased from Invitrogen (Carlsbad, CA, USA). RT reagent kit and Premix Ex Taq were from TAKARA (Dalian, China). Lipofectamine 2000 was purchased from Invitrogen (Carlsbad, CA, USA). Luciferase kit was purchased from Promega (WI, USA). Apoptosis kit was purchased from BD Biosciences (San Jose, CA, USA).

Isolation, identification and culture of pancreatic stellate cells

Primary pancreatic stellate cells were isolated from normal male Sprague–Dawley rats by digestion of pancreatic tissue and Nycodenz density gradient centrifugation [35]. They were cultured at 37°C in a 5% CO2. The medium consisted of Dulbecco’s modified Eagle’s medium/Ham F12 medium (1:1, vol/vol) with 10% FBS (Gibco, 10091155, Waltham, Ma, USA), 100 U/ml penicillin and 100 mg/ml streptomycin.

Sera were collected from female Sprague–Dawley rats used for the experiments.

ELISA

Serum concentrations of TNF-α and IL-6 were determined via ELISA assay kits (R&D, Minneapolis, MN, USA).

Stem-loop RT-PCR to measure micro RNA levels

The samples of pancreatic tissues and primary pancreatic stellate cells were collected with TRIzol reagent (Invitrogen, Carlsbad, CA, USA) to achieve total RNA. Expression of mature miR-15 and miR-16 were assayed using stem-loop RT followed by PCR analysis as previously described [36]. The relative amount of miRNA was normalized to U6 snRNA. The RT primer for miR-15 was GTCGTATCCAGT GCAGGGTGCTCAGGTATTCTGAAGCTGAA AG. The RT primers for miR-16 was GTCGTATCCAGT GCAGGGTGCTCAGGTATTCTGAAGCTGAA AG. The RT primers for U6 was CGTTCACGAAATTGC
GTGTCAT. The qPCR primers for miR-15 were GGCGGT AGCAGCAGCATCAG (forward primer) and GTGCAG GTTCCCGAGGT (reverse primer). The qPCR primers for miR-16 were GGCGTGAGCAGCAGTAAATA (forward primer) and GTGCAGGTCCCGAGGT (reverse primer). The qPCR primers for U6 were GCTTTCGGCAGCACAT ATACTAAAT (forward primer) and CGTTCAGCAAT TTGCGTGTCAT (reverse primer).

RT and qPCR

The samples of pancreatic tissues and primary pancreatic stellate cells were collected with TRIzol reagent (Invitrogen, Carlsbad, CA, USA) to achieve total RNA. 0.5 μg of total RNA was reverse-transcribed to synthesize cDNA using a first-strand cDNA synthesis kit (TAKARA, Dalian, China). qPCR was performed through the ABI PRISM 7500 Fast Sequence Detection System (Applied Biosystems, USA) using the SYBR Green PCR kit (Applied Biosystems, USA). Relative mRNA levels were normalized to GAPDH mRNA, and the fold change for each mRNA was calculated using the ΔΔCt method. The mRNA primers for α-SMA were TTC CAGCCCTCTTTATCG (forward primer) and TTGGCG TACAGGTCCTTC (reverse primer). The mRNA primers for GAPDH were TATCGGACCGCTTGTTAC (forward primer) and CTGTGCCCAGTGAACGGC (reverse primer).

Western blot

Related primary pancreatic stellate cells were harvested by RIPA lysis buffer containing 1 mmol/l PMSF and centrifuged at 12000 rpm for 10 min at 4 °C. All protein sample concentration was determined by the BCA method (Thermo, Carlsbad, CA, USA). The proteins were separated by 10% or 15% of SDS/polyacrylamide gels, which were transferred to the PVDF membranes (Bio-Rad, Hercules, CA, USA). The membranes were blocked in 5% milk for 1 h at RT, then incubated with primary antibodies overnight at 4 °C. The next day, the membranes were washed with TBST for three times, incubated with HRP-labeled secondary antibodies (Cell Signaling, Beverly, MA, USA). The ECL reagents (Thermo, Carlsbad, CA, USA) were added to visualize the chemiluminescence by ECL Plus detection system (Tanon, Shanghai, China). The band densities were analyzed with the ImageJ analysis system.

Immunohistochemistry and immunofluorescence staining

The pancreatic tissues were fixed in 10% formalin, paraffin embedded and mounted to sections. Primary pancreatic stellate cells were seeded in 6-well plates with 5 × 104 cells/well. Cells were transfected with miR-15 and miR-16 mimics. After 48 h, they were fixed with neutral formalin. Both tissues and cells were stained with α-SMA (dilution 1:200), and the nucleus was stained with propidium iodide (PI). The images were captured by fluorescence microscope.

Apoptosis analysis

CCK-8 reagent was purchased from Dojindo laboratories. To measure the double-stranded cleavage of DNA, TUNEL assay was performed with an in-situ cell death detection kit following the manufacturer’s instructions (R&D, Minneapolis, MN, USA). The Annexin-V-FITC/propidium iodide (PI) Apoptosis Detection Kit (BD, San Jose, CA, USA) was used to evaluate cell apoptosis according to the manufacturer’s instruction. TUNEL Assay and Apoptosis Assay. The samples were detected by FACS (BD, San Jose, CA, USA). The experiments were repeated three times.

Caspase-3, caspase-9 activity assay

Primary pancreatic stellate cells were seeded in six-well plates and transfected with miR-15, miR-16, miR-15 inhibitor or miR-16 inhibitor with the company of SAHA. Caspase-3 and caspase-9 activities were detected using commercially available kits (KGA204 and KGA404) from KeyGen BioTech (Jiangsu, China) according to the manufacturer’s instructions. Caspase activity was expressed as a ratio of the absorbance of control cells.

Statistical analysis

Results were presented as mean ± SD, and statistical analysis was performed using Prism GraphPad. Unpaired Student’s t test was used to determine statistical significance unless otherwise indicated, and P value of less than 0.05 was considered significant. *** means P < 0.001.

Results

Vorinostat (SAHA) prevented pancreatic fibrosis in rats of chronic pancreatitis

Rats undergoing repetitive treatment with trinitrobenzene sulfonic acid caused chronic pancreatitis (Fig. 1a). We found that expression of the fibrosis marker GFAP, α-SMA (Fig. 1b) and the inflammation marker TNF-α, IL-6 (Fig. 1c) increased significantly in chronic pancreatitis when compared to controls. However, under the treatment with the HADC inhibitor Vorinostat (also called SAHA), the pancreatic fibrosis phenotypes were rescued remarkably (Fig. 1a, b).
**Fig. 1** Vorinostat (SAHA) prevented pancreatic fibrosis in rats of chronic pancreatitis. 

- **a** Hematoxylin and eosin dyeing of pancreas sections in chronic pancreatitis. 
- **b** Immunofluorescence staining of GFAP (red, up) or α-SMA (green, down) in pancreatic tissues of rats with chronic pancreatitis after treated with Saline or SAHA (25 mg/kg). 
- **c** The levels of TNF-α (up) and IL-6 (down) in serums of rats with or without chronic pancreatitis after treated with Saline or SAHA (25 mg/kg). All data are presented as the mean ± S.D. (n=5).

***P < 0.001, compared with control. Each assay was performed in triplicate.
Vorinostat (SAHA) could restore miR-15 and miR-16 levels in chronic pancreatitis

According to our results, the levels of miR-15 and miR-16 in chronic pancreatitis tissues of patients strongly decreased (Fig. 2a). We confirmed and extended the studies in our animal chronic pancreatitis models. To our surprise, the amounts of miR-15 and miR-16 rebounded when we treated the rats with the HADC inhibitor Vorinostat (Fig. 2b).

HDAC inhibition promoted apoptosis of pancreatic stellate cells and elevated transcription of miR‑15 and miR‑16

To explored how HDAC activities affected the progress of pancreatic fibrosis, we separated the primary pancreatic stellate cells from rats, and the morphology of PSCs showed in Fig S1a, and PSCs was identified by immunofluorescence (Fig S1b, c). As we showed, two different HADC inhibitors, vorinostat (SAHA) or trichostatin A (TSA), dose dependently inhibited the survival of pancreatic stellate cells (Fig. 3a). By FACS, we found HADC inhibitors promoted apoptosis of pancreatic stellate cells indeed (Fig. 3b). And the mRNA (Fig. 3c) and protein (Fig. 3d) levels of α-SMA decreased remarkably when treated with SAHA or TSA, which was consistent with our previous in vitro findings. Interestingly, we found the expression levels of miR-15 and miR-16 in pancreatic stellate cells increased when treated with TSA (Fig. 3e). And the acylation of Histone 3 and Histone 4 was promoted under the incubation of HDAC inhibitors (Fig. 3f), which might induce the transcription of miR-15 and miR-16.

miR-15 and miR-16 promoted apoptosis of pancreatic stellate cells

Since HDAC inhibition could enhance the transcription of miR-15 and miR-16, then how did they regulate the survival of pancreatic stellate cells. We overexpressed them in pancreatic stellate cells and detected apoptosis of them by TUNEL assay and FACS. The results showed that both miR-15 and miR-16 promoted apoptosis of pancreatic stellate cells indeed (Fig. 4b, c). Moreover, cleaved caspase 9 and cleaved caspase 3 increased obviously when miR-15 and miR-16 were overexpressed (Fig. 4d). And the activities of caspase 9 and caspase 3 improved significantly (Fig. 4e). On the contrary, under the treatment of SAHA, the enhanced activities of caspase 9 and caspase 3 were inhibited by miR-15 inhibitor or miR-16 inhibitor (Fig. 4f, h), meanwhile, qPCR was performed to confirm the efficacy of miR-15 inhibitor or miR-16 inhibitor (Fig. 4g). The above results meant that HDAC inhibition promoted apoptosis of pancreatic stellate cells by miR-15 and miR-16.

HDAC inhibition disrupts TGF-β/Smad Signaling by miR-15 and miR-16 to protect against pancreatic fibrosis

Except for the survival of pancreatic stellate cells were regulated by miR-15 and miR-16, we also found that the expression of α-SMA was inhibited at the same time (Fig. 5a, b). Smad5, the major transcription factor of TGF-β, decreased when miR-15 and miR-16 were overexpressed (Fig. 5a). Smad7, another antistatic transcription factor of Smad5, increased as well (Fig. 5a). Similarly, the decreased miR-15 or miR-16 could eliminate the protection of HDAC inhibition to pancreatic fibrosis (Fig. 5c).

miR-15 and miR-16 induce the apoptosis and fibrosis of pancreatic stellate cells by targeting Bcl-2 and Smad5

Through the sequence alignment of TargetScan, we found that it was probable that both Bcl-2 and Smad5 were the target genes of miR-15 and miR-16 (Fig. 6a). The reporter gene assays of 3’UTR and their mutant clones showed us miR-15 and miR-16 could bind and regulate the transcription Bcl-2 and Smad5 (Fig. 6b). The decreased protein levels of them further convinced our hypothesis (Fig. 6c). Furthermore,
HDAC inhibitors promote pancreatic stellate cell apoptosis and relieve pancreatic fibrosis…

The protein level of Bcl-2 and Smad5 in our animal chronic pancreatitis models were detected, and the result showed that Bcl-2 and Smad5 upregulated in chronic pancreatitis model and decreased while treated with SAHA (Fig. 6d), and negatively correlated with miR-15 or miR-16.

Discussion

For so long, the relation between acute pancreatitis and chronic pancreatitis has been a great debate. Some evidences revealed that chronic pancreatitis was the result of repeated episodes of acute pancreatitis [37]. And there are four prominent theories of chronic pancreatitis pathogenesis, the toxic-metabolic theory, the oxidative stress hypothesis, the stone and duct obstruction theory and the necrosis-fibrosis hypothesis [1]. Pathological speaking, chronic pancreatitis is a dynamic inflammatory process that is characterized by progressive fibrosis, pain and/or loss of exocrine and endocrine functions [38, 39].

Now Alcohol and some oxidized by-products have been devised to common risk modifiers for chronic pancreatitis [40, 41]. Although the clinical, morphological, and etiological characteristics of chronic pancreatitis are well known, the pathogenic mechanism has remained elusive. In this study, apoptosis and fibrosis transformation regulated by miR-15 and miR-16 were elucidated to help understand the progress of chronic pancreatitis.

Recently studies in vitro and in vivo have shown the vital role of activated PSCs in CP. Following their initial
activation, when injury or inflammation are sustained or repeated, the activation of PSCs is retained, assisting the development of pancreatic fibrosis; on the contrary, if the injury or inflammation are suppressed, PSCs may undergo apoptosis or convert to the quiescent stage [42]. HDAC is crucial because DNA expression is regulated by acetylation and de-acetylation of histone during the process of PSCs activation [43]. According to studies, the expression of
many miRNAs was changed during PSCs activation, such as miR-324, miR-34c, miR-484, miR-15 and miR-16, leading to the pathological changes like pancreatic fibrosis [30]. Among them, miR-484 would regulate fibrosis by targeting IL-8, while miR-34c could target notch signaling pathway, and miR-324-5p was presented to directly target specificity protein 1 and E26 transformation-specific 1, which played important roles in ECM signaling pathway [30].

Our results show that miR-15 and miR-16 are down-regulated both in human patients and PSCs from rats with CP along with symptoms of fibrosis and inflammation. The application of HDAC inhibitors, SAHA or TSA, demonstrates that miR-15 and miR-16 are regulated by abnormal activation of HADC in PC. And Bcl-2, one of the most important anti-apoptotic proteins, is proved to be a target gene of miR-15 and miR-16. Then the progress of apoptosis is inhibited in CP, and the redundant PSCs with defects will gradually cause some damage. On the other hand, TGF-β is important in many cellular activities, only a few TGF-β activating pathways are already known, and the full mechanism behind this activation pathways is not yet well understood. Activated TGF-β signaling levels could cause several complications including inflammation, autoimmune disorders, fibrosis, cancer and cataracts. Smad5, a kind of receptor-regulated Smads, is a signal transducer for receptors of the TGF-β. And it is able to translocate into the cell nucleus to induce transcription of different effectors then regulate cell development and growth. Coincidently, Smad5 is also regulated by miR-15 and miR-16 in our study. The results above explained the pathogenesis of CP well in a completely new point of view, which enriches the thoughts for the treatment of CP.

Fig. 5 HDAC inhibition disrupts TGF-β/Smad Signaling by miR-15 and miR-16 to protect against pancreatic fibrosis. a The protein levels and the related quantification of α-SMA, SMAD5 and SMAD7 in PSCs after overexpression of miR-15 or miR-16. b Immunofluorescence staining of α-SMA in PSCs after overexpression of miR-15 or miR-16. c The protein levels and the related quantification of α-SMA, SMAD5 and SMAD7 in PSCs after transfected with miR-15 inhibitor or miR-16 inhibitor with or without SAHA. All data are presented as the mean ± S.D. (n = 3). ***P < 0.001, compared with control. Each assay was performed in triplicate.
**Author contributions** All authors have contributed to this article as follows: FS participated in the design and coordination of the study, TJ drafted the manuscript; FS, TJ and WF conceived the experiments. TJ, XZ, KZ and XZ performed the experiments. TJ and WF analyzed the data. FS, TJ and WF wrote the manuscript. TJ and WF contributed equally to this manuscript. All authors read and approved the final version of the manuscript.

---

**Fig. 6** miR-15 and miR-16 induce the apoptosis and fibrosis of pancreatic stellate cells by targeting Bcl-2 and Smad5. **a** miR-15b and miR-16 share conserved binding sites in 3′ UTR of Bcl-2 and SMAD5. **b** The luciferase activity of either wildtype (Wt) or mutant (Mut) 3′ UTR of Bcl-2 and SMAD5 in PSCs after overexpression of miR-15 or miR-16. **c** The protein levels and the related quantification of Bcl-2 and SMAD5 in PSCs after overexpression of miR-15 or miR-16. **d** The protein levels and the related quantification of Bcl-2 and SMAD5 in pancreatic tissues of rats with or without chronic pancreatitis after treated with Saline or SAHA (25 mg/kg). All data are presented as the mean±S.D. (n = 3). ***P < 0.001, compared with control. Each assay was performed in triplicate.
Funding The authors declare that there are no sources of funding to be acknowledged.

Data availability All relevant data are within the paper.

Compliance with ethical standards

Conflict of interest The authors confirm that there are no conflicts of interest.

Ethical approval All animal experiments were conducted in accordance with the institutional guidelines from the Care and Use of Laboratory Animals of Changzhou City No. 1 People’s Hospital. The animals’ welfare and the experimental procedures were approved by the Animal Ethics Committee of Changzhou City No. 1 People’s Hospital.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Stevens T, Conwell DL, Zuccaro G. Pathogenesis of chronic pancreatitis: an evidence-based review of past theories and recent developments. Am J Gastroenterol. 2004;99(11):2256–70.
2. Duggan SN. Negotiating the complexities of exocrine and endocrine dysfunction in chronic pancreatitis. Proc Nutr Soc. 2017;76(4):484–94.
3. Hayakawa T, Naruse S, Kitagawa M, Ishiguro H, Jin CX, Kondo T. Clinical evidence of pathogenesis in chronic pancreatitis. J Hepato Biliary Pancreat Surg. 2002;9(6):669–74.
4. Zhang GW, Lin JH, Qian JP, Zhou J. Analysis of risk factors for pancreatic duct stones formation in patients with alcoholic chronic pancreatitis. Pancreatology. 2014;14(2):109–13.
5. Iredale JP. Matrix turnover in fibrogenesis. Hepatogastroenterology. 1996;43(7):56–71.
6. Neuschwander-Tetri BA, Bridle KR, Wells LD, Marcu M, Ramm GA. Repetitive acute pancreatic injury in the mouse induces pro-collagen alpha1(I) expression colocalized to pancreatic stellate cells. Lab Invest. 2000;80(2):143–50.
7. Apte M, Pirola R, Wilson J. The fibrosis of chronic pancreatitis: new insights into the role of pancreatic stellate cells. Antioxid Redox Signal. 2011;15(10):2711–22.
8. Esteller M. CpG island methylation and histone modifications: biology and clinical significance. Ernst Schering Res Found Workshop. 2006:57:115–26.
9. Cho HM, Seok YM, Lee HA, Song M, Kim I. Repression of transcriptional activity of forkhead box O1 by histone deacetylase inhibitors ameliorates hyperglycemia in type 2 diabetic rats. Int J Mol Sci. 2018;19(11):3539.
10. Yoon S, Kang G, Eom GH. HDAC inhibitors: therapeutic potential in fibrosis-associated human diseases. Int J Mol Sci. 2019;20(6):1329.

11. Sun X, Xie Y, Sun X, Yao Y, Li H, Li Z, et al. The selective HDAC6 inhibitor Nexturastat A induces apoptosis, overcomes drug resistance and inhibits tumor growth in multiple myeloma. Biosci Rep. 2019;39(3):BSR20181916.
12. Chen WY, Zhang H, Gatta E, Glover EJ, Pandey SC, Lasek AW. The histone deacetylase inhibitor suberylanilide hydroxamic acid (SAHA) alleviates depression-like behavior and normalizes epigenetic changes in the hippocampus during ethanol withdrawal. Alcohol. 2019;78:79–877.
13. Purdali E, Sanchez-Dulflues G, Gomez-Puerto MC, Ten Dijke P. TGF-beta-induced endothelial-mesenchymal transition in fibrotic diseases. Int J Mol Sci. 2017;18(10):2157.
14. Zhou Q, Xia S, Ou F, Hu F, Wang Z, Ni Y, et al. Transforming growth factor-beta in pancreatic diseases: mechanisms and therapeutic potential. Pharmacol Res. 2019;142:58–69.
15. Yoo BM, Yeo M, Oh TY, Choi JH, Kim WW, Kim JH, et al. Amelioration of pancreatic fibrosis in mice with defective TGF-beta signaling. Pancreas. 2005;30(3):e71–e7979.
16. Xu XF, Liu F, Xiong QJ, Fan JW, Wu N, Zhu LJ, et al. Respective roles of the mitogen-activated protein kinase (MAPK) family members in pancreatic stellate cell activation induced by transforming growth factor-beta1 (TGF-beta1). Biochem Biophys Res Commun. 2018;501(2):365–73.
17. Tjomsland V, Pomianowska E, Aasrum M, Sandnes D, Verbeke CS, Ghadhaug IP. Profile of MMP and TIMP expression in human pancreatic stellate cells: regulation by IL-1alpha and TGFbeta and implications for migration of pancreatic cancer cells. Neoplasia. 2016;18(7):447–56.
18. Hill CS. Transectional control by the SMADs. Cold Spring Harb Perspect Biol. 2016;8(10):a022079.
19. Gaarenstroom T, Hill CS. TGF-beta signaling to chromatin: how Smads regulate transcription during self-renewal and differentiation. Semin Cell Dev Biol. 2014:32:107–18.
20. Luo L, Li N, Lv N, Huang D. SMAD7: a timer of tumor progression targeting TGF-beta signaling. Tumour Biol. 2014;35(9):8379–85.
21. Yan X, Chen YG. Smad7: not only a regulator, but also a cross-talk mediator of TGF-beta signalling. Biochem J. 2011;434(1):1–10.
22. Haas SL, Fitzner B, Jaster R, Wiercinska E, Gaitantzi H, Jesnowski R, et al. Transforming growth factor-beta induces nerve growth factor expression in pancreatic stellate cells by activation of the ALK5 pathway. Growth Factors. 2009;27(5):289–99.
23. Hou XJ, Jin ZD, Jiang F, Zhu JW, Li ZS. Expression of Smad7 and Smad ubiquitin regulatory factor 2 in a rat model of chronic pancreatitis. J Dig Dis. 2015;16(7):408–15.
24. Xu M, Cai J, Wei H, Zhou M, Xu P, Huang H, et al. Scoparone protects against pancreatic fibrosis via TGF-beta/Smad signaling in rats. Cell Physiol Biochem. 2016;40(1–2):277–86.
25. Santovito D, Egea V, Weber C. Small but smart: microRNAs orchestrate atherosclerosis development and progression. Biochim Biophys Acta. 2016;1861(12 Pt B):2075–86.
26. Li X, Nie J, Mei Q, Han WD. MicroRNAs: novel immunotherapeutic targets in colorectal carcinoma. World J Gastroenterol. 2016;22(23):5317–31.
27. Singh RP, Massachi I, Manickavel S, Singh S, Rao NP, Hasan S, et al. The role of miRNA in inflammation and autoimmunity. Autoimmun Rev. 2013;12(12):1160–5.
28. Rederstorff M, Hutenhofer A. Small non-coding RNAs in disease development and host-pathogen interactions. Curr Opin Mol Ther. 2010;12(6):684–94.
29. Torres JL, Novo-Veleiro I, Manzanedo L, Alvela-Suarez L, Macias R, Laso FJ, et al. Role of microRNAs in alcohol-induced liver disorders and non-alcoholic fatty liver disease. World J Gastroenterol. 2018;24(36):4104–18.
30. Wang D, Xin L, Lin JH, Liao Z, Ji JT, Du TT, et al. Identifying miRNA-mRNA regulation network of chronic pancreatitis.
based on the significant functional expression. Medicine. 2017;96(21):e6668.

31. Hu LH, Ji JT, Li ZS. Potential application of miRNAs as diagnostic and therapeutic tools in chronic pancreatitis. J Cell Mol Med. 2015;19(9):2049–57.

32. Shen J, Wan R, Hu G, Yang L, Xiong J, Wang F, et al. miR-15b and miR-16 induce the apoptosis of rat activated pancreatic stellate cells by targeting Bcl-2 in vitro. Pancreatology. 2012;12(2):91–9.

33. Jin W, Chen F, Wang K, Song Y, Fei X, Wu B. miR-15a/miR-16 cluster inhibits invasion of prostate cancer cells by suppressing TGF-beta signaling pathway. Biomed Pharmacother. 2018;104:637–44.

34. Puig-Divi V, Molero X, Salas A, Guarner F, Guarner L, Malaglada JR. Induction of chronic pancreatic disease by trinitrobenzene sulfonic acid infusion into rat pancreatic ducts. Pancreas. 1996;13(4):417–24.

35. Li CX, Cui LH, Zhuo YZ, Hu JG, Cui NQ, Zhang SK. Inhibiting autophagy promotes collagen degradation by regulating matrix metalloproteinases in pancreatic stellate cells. Life Sci. 2018;208:276–83.

36. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005;33(20):e179.

37. Whitcomb DC. Hereditary pancreatitis: new insights into acute and chronic pancreatitis. Gut. 1999;45(3):317–22.

38. Hammad AY, Ditillo M, Castanon L. Pancreatitis. Surg Clin N Am. 2018;98(5):895–913.

39. Drewes AM. Understanding and treatment of chronic pancreatitis. World J Gastroenterol. 2013;19(42):7219–21.

40. Ammann RW, Heitz PU, Kloppel G. Course of alcoholic chronic pancreatitis: a prospective clinicomorphological long-term study. Gastroenterology. 1996;111(1):224–31.

41. Youssef N, Petitjean B, Bonte H, Terris B, de Saint Maur PP, Flejou JF. Non-alcoholic duct destructive chronic pancreatitis: a histological, immunohistochemical and in-situ apoptosis study of 18 cases. Histopathology. 2004;44(5):453–61.

42. Talukdar R, Tandon RK. Pancreatic stellate cells: new target in the treatment of chronic pancreatitis. J Gastroenterol Hepatol. 2008;23(1):34–41.

43. Bombardo M, Chen R, Malagola E, Saponara E, Hills AP, Graf R, et al. Inhibition of class I histone deacetylases abrogates tumor growth factor beta expression and development of fibrosis during chronic pancreatitis. Mol Pharmacol. 2018;94(2):793–801.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.